Hygea VCT
VC Fund
Brackley, United Kingdom
Hygea VCT is a VC fund in Brackley focused on Biotechnology and Health Care. Hygea vct provides investors with access to a diversified portfolio of emerging and established MedTech companies qualifying for investment by a VCT. The board has a strong track record of investing in this area and has a network of personnel with successful P&L responsibility experience in the MedTech sector, both in the UK andinternationally.A key feature of the Hygea investment approach is to ensure that portfolio companies are developed as solutions companies i.e. compete on the basis of value provided to customers (not price) by providing better patient outcomes at lower total cost. The effect of this approach is that portfolio companies tend to be focused around medical devices, drug delivery systems, diagnostics and technology based support services - standalone molecule development companies do not generally qualify as solutions companies.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Hygea VCT invests in
Stages Hygea VCT invests in
Countries Hygea VCT invests in
Investment Focus
Industry
- Biotechnology 3 (43%)
- Health Care 2 (29%)
- Medical 1 (14%)
- Video Games 1 (14%)
- Therapeutics 1 (14%)
Stage
- Funding Round 2 (29%)
- Series A 1 (14%)
- Series B 1 (14%)
- Series D 1 (14%)
- Private Equity 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Glide Pharmaceutical Technologies is a clinical stage development company that focuses on solid dose formulations of therapeutics and vaccines. The company develops SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, andanthrax and influenza vaccines. Glide Pharmaceutical Technologies was formerly known as Caretek Medical. | $4.2M / Feb 01, 2017 | ||
| Eykona Medical develops and markets portable three dimensional imaging systems. Its systems are used to capture environments for videogames and in medical imaging for dermatological care. The company is based in Oxford, the United Kingdom. | $1.6M / Series A / Sep 24, 2010 | ||
| Glide Pharmaceutical Technologies is a clinical stage development company that focuses on solid dose formulations of therapeutics and vaccines. The company develops SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, andanthrax and influenza vaccines. Glide Pharmaceutical Technologies was formerly known as Caretek Medical. | $4.3M / Series D / Mar 17, 2010 | ||
| Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012. | $1.7M / May 25, 2005 | ||
| Purely Proteins commercial database model for delivering proteomatics information to clients has already been exemplified through 3 non-exclusive licences of database modules to biotech and pharma partners.Purely Proteins Protein Purification Partnerships are backed by the experience of previous high-value relationships between the Institute ofBiotechnology, University of Cambridge and major pharmaceutical companies. | $3.6M / Series B / Dec 01, 2004 | ||
| Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012. | $1.7M / Apr 27, 2004 | ||
| DxS (now a Qiagen company) is a personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies, DxS will support the development and sales of targeted cancer therapies by providing companion diagnostic products and services.Since its founding in 2001, DxS has experienced considerable growth and firmly established itself as a leader in companion diagnostics, having recently secured deals with leading healthcare companies such as Amgen, Boehringer Ingelheim, and AstraZeneca. In addition, DxS has an exclusive agreement with Roche Diagnostics for the global distribution of its diagnostic products. DxS has a portfolio of cancer mutation products including both diagnostic and assays for research use. The TheraScreen® range of CE-marked (IVD) diagnostic* kits can identify genetic tumor mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS currently produce two diagnostic kits, TheraScreen K-RAS and TheraScreen EGFR29. The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of colorectal cancer. DxS was acquired by Qiagen (NASDQ : QGEN) and continues to operate from the heart of Manchester’s Technology Quarter in the UK. | Private Equity / Jan 01, 2004 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Hygea VCT invest in?
Hygea VCT invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series A stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Hygea VCT last invest?
The most recent investment recorded for Hygea VCT closed in Feb 2017. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
